Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

Cancer

Volumn 123, Issue 15, 2017, Pages 2875-2880

  Nicolini, Franck E ^a   Basak, Grzegorz W ^b   Kim, Dong Wook ^c   Olavarria, Eduardo ^d   Pinilla Ibarz, Javier ^e   Apperley, Jane F ^d   Hughes, Timothy ^f   Niederwieser, Dietger ^g   Mauro, Michael J ^h   Chuah, Charles ⁱ   Hochhaus, Andreas ^j   Martinelli, Giovanni ^k   DerSarkissian, Maral ^l   Duh, Mei Sheng ^l   McGarry, Lisa J ^m   Kantarjian, Hagop M ⁿ   Cortes, Jorge E ⁿ  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c The Catholic University of Korea   (South Korea)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j JENA UNIVERSITY HOSPITAL   (Germany)

^k L e A Seragnoli Institute of Hematology   (Italy)

^l ANALYSIS GROUP   (United States)

^m ARIAD PHARMACEUTICALS INC   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

allogeneic stem cell transplantation (allo SCT); chronic myeloid leukemia (CML); Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL); ponatinib; threonine to isoleucine mutation at codon 315 (T315I)

Indexed keywords

PONATINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CODON; FEMALE; GENE MUTATION; GEOGRAPHY; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME POSITIVE CELL; POST HOC ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX; SURVIVAL RATE; AGED; ALLOTRANSPLANTATION; BLAST CRISIS; COMPARATIVE STUDY; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTIVARIATE ANALYSIS; MUTATION; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; FEMALE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; PYRIDAZINES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 85017543367     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30558     Document Type: Article

References (15)

1. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2010;95:8-12.
2. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116:3409-3417.
3. Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph(+)ALL—role of ponatinib. Biologics. 2014;8:243-254.
4. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401-412.
5. O'Hare T. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
6. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783-1796.
7. Cortes JE, Kantarjian HM, Rea D, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015;121:1637-1644.
8. Nicolini FE, Ibrahim AR, Soverini S, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510-1516.
9. Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009;114:5271-5278.
10. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118:5697-5700.
11. Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75:45-49.
12. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
13. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-570.
14. Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547-1555.
15. Gratwohl A, Pfirrmann M, Zander A, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2015;30:562-569.